A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain

Journal of Molecular Neuroscience

Volumn 24, Issue 2, 2004, Pages 247-255

  Okamura, Nobuyuki ^a,b   Suemoto, Takahiro ^a   Shiomitsu, Tsuyoshi ^a   Suzuki, Masako ^a   Shimadzu, Hiroshi ^a   Akatsu, Hiroyasu ^c   Yamamoto, Takayuki ^c   Arai, Hiroyuki ^b   Sasaki, Hidetada ^b   Yanai, Kazuhiko ^b   Staufenbiel, Matthias ^d   Kudo, Yukitsuka ^a   Sawada, Tohru ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA CITY UNIVERSITY   (Japan)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; Amyloid protein; Imaging; Neurofibrillary tangles; Positron emission tomography; Senile plaques

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PROTEIN; BENZOXAZOLE DERIVATIVE; BF 133; BF 140; BF 145; BF 151; FLUORESCENT DYE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; FLUORINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN; CHEMICAL LABELING; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG SPECIFICITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INJECTION; MALE; MOUSE; NEURITIS; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SENILE PLAQUE; STAINING; SYMPTOM; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DIAGNOSTIC IMAGING; METABOLISM; METHODOLOGY; PATHOLOGY;

MUS MUSCULUS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BENZOXAZOLES; BRAIN; DIAGNOSTIC IMAGING; FEMALE; FLUORESCENT DYES; FLUORINE COMPOUNDS; HUMANS; MALE; MICE; MICE, TRANSGENIC; MOLECULAR STRUCTURE; POSITRON-EMISSION TOMOGRAPHY; SENILE PLAQUES;

EID: 16844364781     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:24:2:247     Document Type: Article

References (30)

1. Agdeppa E. D., Kepe V., Liu J., Flores-Torres S., Satyamurthy N., Petric A., et al. (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J. Neurosci. 21, RC189.
2. Bacskai B. J., Kajdasz S. T., Christie R. H., Carter C., Games D., Seubert P., et al. (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7, 369-372.
3. Bacskai B. J., Klunk W. E., Mathis C. A., and Hyman B. T. (2002) Imaging amyloid-β deposits in vivo. J. Cereb. Blood Flow Metab. 22, 1035-1041.
4. Cheng Y. and Prusoff W. H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108.
5. Crystal A. S., Giasson B. I., Crowe A., Kung M. P., Zhuang Z. P., and Trojanowski J. Q. (2003) A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J. Neurochem. 86, 1359-1368.
6. Du Y., Wei X., Dodel R., Sommer N., Hampel H., Gao F., et al. (2003) Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity. Brain 126, 1935-1939.
7. Engler H., Blomqvist G., Bergstrom M., Langstrom B., Klunk W., Debnath M., et al. (2002) First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. Neurobiol. Aging 23, S1568.
8. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
9. Helmuth L. (2002) New Alzheimer's treatments that may ease the mind. Science 297, 1260-1262.
10. Kitamoto T., Ogomori K., Tateishi J., and Prusiner S. B. (1987) Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab. Invest. 57, 230-236.
11. Klunk W. E., Bacskai B. J., Mathis C. A., Kajdasz S. T., McLellan M. E., Frosch M. P., et al. (2002) Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropathol. Exp. Neurol. 61, 797-805.
12. Klunk W. E., Wang Y., Huang G. F., Debnath M. L., Holt D. P ., Shao L., et al. (2003) The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J. Neurosci. 23, 2086-2092.
13. Kung H. F., Kung M. P., Zhuang Z. P., Hou C., Lee C. W., Plossl K., et al. (2003) Iodinated tracers for imaging amyloid plaques in the brain. Mol. Imaging Biol. 5, 418-426.
14. Kung M. P., Hou C., Zhuang Z. P., Zhang B., Skovronsky D., Trojanowski J. Q., et al. (2002) IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res. 956, 202-210.
15. Kung M. P., Skovronsky D. M., Hou C., Zhuang Z.P., Gur T. L., Zhang B., et al. (2003a) Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients. J. Mol. Neurosci. 20, 15-24.
16. Kung M. P., Zhuang Z. P., Hou C., Jin L. W., and Kung H. F. (2003b) Characterization of radioiodinated ligand binding to amyloid beta plaques. J. Mol. Neurosci. 20, 249-254.
17. Lee C. W., Kung M. P., Hou C., and Kung H. F. (2003) Dimethylamino- fluorenes: ligands for detecting beta-amyloid plaques in the brain. Nucl. Med. Biol. 30, 573-580.
18. Mathis C. A., Bacskai B. J., Kajdasz S. T., McLellan M. E., Frosch M. P., Hyman B. T., et al. (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett. 12, 295-298.
19. Morris J. C., Storandt M., McKeel D. W., Jr., Rubin E. H., Price J. L., Grant E. A., et al. (1996) Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46, 707-719.
20. 11C-Labeled stilbene derivatives as Aβ-aggregate- specific PET imaging agents for Alzheimer's disease. Nucl. Med. Biol. 30, 565-571.
21. Price J. L. and Morris J. C. (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 45, 358-368.
22. Selkoe D. J. (2000) Imaging Alzheimer's amyloid. Nat. Biotechnol. 18, 823, 824.
23. Shoghi-Jadid K., Small G. W., Agdeppa E. D., Kepe V., Ercoli L. M., Siddarth P., et al. (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 10, 24-35.
24. Skovronsky D. M., Zhang B., Kung M. P., Kung H. F., Trojanowski J. Q., and Lee V. M. (2000) In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 97, 7609-7614.
25. Small G. W., Agdeppa E. D., Kepe V., Satyamurthy N., Huang S.- C., and Barrio J. R. (2002) In vivo brain imaging of tangle burden in humans. J. Mol. Neurosci. 19, 323-327.
26. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K. H., Mistl C., Rothacher S., et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 94, 13287-13292.
27. Suemoto T., Okamura N., Shiomitsu T., Suzuki M., Shimadzu H., Akatsu H., et al. (2004) In vivo amyloid-β labeling in a model mouse with BF-108. Neurosci. Res. 48, 65-74.
28. Trojanowski J. Q. (2002) Emerging Alzheimer's disease therapies: focusing on the future. Neurobiol. Aging 23, 85-990.
29. Vickers J. C., Dickson T. C., Adlard P. A., Saunders H. L., King C. E., and McCormack G. (2000) The cause of neuronal degeneration in Alzheimer's disease. Prog. Neurobiol. 60, 139-165.
30. Wu C. W., Liao P. C., Lin C., Kuo C. J., Chen S. T., Chen H. I., et al. (2003) Brain region-dependent increases in beta-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits. J. Neural. Transm. 110, 641-649.